retatrutide 2025 trial results October 27, 2025: U.K. regulators bust illicit site making unlicensed and tirzepatide pens – Partnership for Safe Medicines Triple hormone receptor agonist retatrutide

However, no consistent inter-group differences were observed in reproductive outcomes, such as menstrual frequency or hormonal profiles, and adverse effects were primarily gastrointestinal (108)

Electrolyte supplementation may be appropriate for those experiencing significant diarrhea

What the clinical trial numbers do not capture is the real-world experience where many patients on various semaglutide doses report sulfur burps that come and go, particularly in the first few weeks and after dose escalations

We read every question and use them to inform our upcoming content, though we are unable to respond to each specific question.